---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-001176"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:40:09.079768+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# VolitionRx raises $7.525M in public offering of 4.3M shares plus full over-allotment

## Summary
- Gross proceeds $7.525M from 4,300,000 shares at $1.75/share; net ~$8.0M after underwriting discount.
- Underwriter exercised option for 645,000 additional shares, bringing total to 4,945,000 shares.
- Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential acquisitions.
- Preliminary unaudited cash and equivalents of ~$10.9M as of Dec 31, 2022.
- Offering led by Newbridge Securities; closed Feb 22, 2023.

## SEC filing metadata
- accession: 0001477932-23-001176
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793223001176/0001477932-23-001176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793223001176/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-001176
- JSON: https://secwatch.observer/filing/0001477932-23-001176.json
- Plain text: https://secwatch.observer/filing/0001477932-23-001176.txt

## Key facts
- Material Agreements
  VOLITIONRX LTD entered into Underwriting Agreement with Newbridge Securities Corporation (effective 2023-02-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Newbridge Securities Corporation
  - Effective: 2023-02-17
  source text: On February 17, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”) pursuant to which the Company agreed to issue and sell an aggregate of 4,300,000 shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793223001176/0001477932-23-001176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.